Brief: CHMP Has Adopted A Negative Opinion For Omburtamab For Treatment Of CNS/LM Metastasis From Neuroblastoma In Europe
16/12/2022 21:03
Dec 16 (Reuters) - Y-mAbs Therapeutics Inc YMAB.O :
* CHMP HAS ADOPTED A NEGATIVE OPINION FOR OMBURTAMAB FOR
TREATMENT
OF CNS/LM METASTASIS FROM NEUROBLASTOMA IN EUROPE
Source text for Eikon: ID:nGNXbdfLS8
Further company coverage: YMAB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Y-mAbs Therapeutics
See all newsY-mAbs Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview
Y-mAbs Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Y-mAbs Therapeutics' Q2 revenue falls 14%
Brief: Serb Pharmaceuticals Agrees To Acquire Y-Mabs Therapeutics
Y-mAbs Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary